Asp Isotopes INC 10-Q quarterly reports

ASP Isotopes Inc. filed its Q2 2026 Form 10-Q, detailing increased revenues from recent acquisitions but also significant operating losses and ongoing financial covenant concerns.

ASP Isotopes Inc. filed its Q1 2026 Form 10-Q, detailing significant operational expansion through acquisitions and continued investment in R&D, alongside a substantial increase in operating expenses.

ASP Isotopes Inc. reported a significant net loss for Q3 2025, primarily due to non-cash fair value adjustments, while advancing strategic acquisitions and its Quantum Leap Energy spin-off plans.

ASP Isotopes Inc. reported a significantly wider net loss in Q2 2025 despite revenue growth, driven by increased operating expenses and fair value adjustments, while advancing key strategic initiatives in nuclear fuels and medical isotopes.

ASP Isotopes Inc. files its 10-Q report for the quarter ended March 31, 2025, detailing financial results and strategic advancements, including agreements with TerraPower and Renergen.

ASP Isotopes Inc. reports a net loss for the third quarter of 2024, while making progress in its isotope enrichment plant development and commercialization efforts.

ASP Isotopes Inc. reports its second quarter 2024 results, highlighting revenue growth from the PET Labs acquisition and ongoing development of isotope enrichment technologies.

ASP Isotopes Inc. reports its first quarter 2024 results, highlighting revenue generation from the PET Labs acquisition and ongoing development of isotope enrichment technologies.